Given the significant effectiveness of αCD38 antibody therapy in reducing tumor burden, albeit without achieving a complete cure, we endeavored to investigate whether residual CTCL tumor cells following treatment displayed diminished CD38 expression in comparison to those that persisted after IgG isotype treatment. This evidence concerns the gene CD38 and neoplasm.